Clinical Trial Update: Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 long-term study update for CP-690,550 in ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2021-09-17